Atea Pharma Q1 net loss narrows to $34.3M; cash $425M; Phase 3 HCV trial enrolling

Atea Pharmaceuticals, Inc.

2025-Q1 EPS reported -$0.40

Net loss $34.3M ($0.40/share) vs $63.2M ($0.75) in Q1 2024; R&D expense down 49% to $29.6M.
Cash, equivalents and marketable securities $425.4M at March 31, down from $454.7M at Dec 31.
Phase 3 C-BEYOND HCV trial enrolling; second Phase 3 C-FORWARD expected mid-2025.
Strategic alternatives review with Evercore ongoing; workforce reduced ~25% to save ~$15M through 2027.
Board authorized $25M share repurchase; Arthur Kirsch and Howard Berman appointed to board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.